Ebola Contract Drives 70 Percent Rise in Tekmira's Q1 Revenues; Supports LNP Scale-up
May 12, 2011
Ebola Contract Drives 70 Percent Rise in Tekmira's Q1 Revenues; Supports LNP Scale-up
Tekmira officials said that under the Ebola contract, the company has been able to scale up its lipid nanoparticle technology to support late clinical development and therapeutic manufacturing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira Takes Hit on Stop-Work Order Related to US Government Ebola Contract
August 9, 2012 / Gene Silencing News - Tekmira Delays Clinical Trial for Cholesterol Drug as it Evaluates Alternative LNP Formulations
September 16, 2010 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to OSU, Tekmira, Nitto Denko, and More
June 6, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Novartis, Tekmira, and More
May 23, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News